United States Patent 10,980,886: Claim Scope, Patent Landscape, and Generic Entry Risk

United States Patent No. 10,980,886 covers semi-solid or liquid polyorthoester compositions containing specified amino-amide local anesthetics, maleic acid, and N-methyl-2-pyrrolidone or dimethyl sulfoxide. The central limitation is a mixed salt-base state in which maleic acid is present below equimolar concentration relative to the anesthetic and the composition is substantially free of anesthetic crystals. The claims are formulation claims, not claims to bupivacaine or ropivacaine as active ingredients generally.

The strongest practical coverage is directed to injectable, extended-release formulations containing bupivacaine or ropivacaine in a polyorthoester matrix with maleic acid and an aprotic solvent. The patent does not, on the face of the supplied claims, require a second active pharmaceutical ingredient, a particular release duration, a particular route of administration, or a specific commercial product.

What does United States Patent 10,980,886 protect?

Patent 10,980,886 protects compositions that satisfy all of the following elements:

Required element	Scope
Polymer	A polyorthoester
Acid component	Maleic acid
Solvent	NMP or DMSO
Active agent	One of eight specified amino-amide anesthetics
Acid ratio	Maleic acid is present in less than an equimolar amount relative to the anesthetic
Physical state	The anesthetic is present as a mixed salt-base
Solid-state limitation	The composition is substantially free of crystals of the anesthetic

Claim 1 is an open-ended “comprising” claim. A product can therefore contain additional polymers, excipients, active ingredients, preservatives, stabilizers, or release-modifying agents and still potentially fall within the claim if every required element is present.

The claim covers both dispersed and solubilized drug. Claim 7 narrows the composition to a solubilized formulation, while claim 6 narrows it to a semi-solid composition.

How broad is claim 1 of Patent 10,980,886?

Claim 1 is materially broader than the dependent claims because it does not limit the polyorthoester to a particular structural formula and does not limit the anesthetic to bupivacaine or ropivacaine.

The covered anesthetics are:

Bupivacaine
Levobupivacaine
Dibucaine
Mepivacaine
Procaine
Lidocaine
Tetracaine
Ropivacaine

The claim applies whether the active agent is dispersed in the polymer or solubilized in the composition. It also covers an active ingredient added in free-base form if the final composition meets the mixed salt-base and crystal-free limitations.

The key narrowing language is the requirement that maleic acid be below equimolar concentration. A formulation containing maleic acid at a one-to-one molar ratio or higher may fall outside the literal scope of claim 1, although the overall formulation and claim construction would determine whether an infringement theory based on equivalents is viable.

What are the limitations of the mixed salt-base requirement?

The mixed salt-base limitation is central to both infringement analysis and validity analysis.

A formulation must contain the anesthetic in a state that is neither exclusively free base nor exclusively a fully neutralized maleate salt. The claim requires a composition in which the anesthetic is present as a mixed salt-base. That limitation raises several technical questions:

Whether the mixed salt-base state is defined by formulation stoichiometry, molecular speciation, or both.
Whether the relevant ratio is measured at manufacture or in the finished product.
Whether the ratio is calculated using total maleic acid, unreacted maleic acid, or chemically associated maleic acid.
Whether the mixed state remains stable during storage.
Whether analytical methods such as NMR, titration, chromatography, or solid-state spectroscopy are required to establish the claimed state.

A generic developer could attempt to design around this limitation by using a different acid, eliminating acid altogether, using a fully neutralized salt, or selecting a formulation in which the active ingredient remains demonstrably in free-base form. Those approaches may create separate formulation and regulatory issues.

What do claims 2 through 7 add?

Claim 2: bupivacaine and ropivacaine

Claim 2 narrows the active agent to bupivacaine or ropivacaine. It is commercially important because these are the two anesthetics most directly associated with long-acting local-anesthetic development.

The claim can cover racemic bupivacaine and ropivacaine, subject to the ordinary meaning of the active-agent terms and the patent’s specification. Claim 2 does not require a particular concentration, dose, administration site, delivery device, or release profile.

Claim 3: free-base addition

Claim 3 requires that the active agent be added to the composition in free-base form. This is a process-of-manufacture limitation incorporated into a composition claim.

The claim does not necessarily cover every product that ultimately contains the same mixed salt-base state. A product manufactured by adding bupivacaine hydrochloride, for example, may not satisfy this limitation unless the claim is interpreted to focus on the composition rather than the manufacturing history. The distinction would depend on claim construction and evidence regarding whether “added ... in its free base form” describes the resulting composition or the manufacturing step.

Claim 4: defined polyorthoester genus

Claim 4 limits the polymer to polyorthoesters represented by Formulas I, II, III, or IV. The formulas create a broad structural genus based on:

The identity of linker group R.
Alkyl substituents.
Polymer chain length.
Alpha-hydroxy acid subunits.
Polyether or polyester segments.
Alkylene groups.
Amide, imide, urea, or urethane-containing diol residues.

The claim is technically broad because it covers multiple polymer architectures and a range of molecular-weight and compositional parameters. It is narrower than claim 1 but remains capable of capturing multiple polymer families used for biodegradable controlled release.

Claim 5: Formula III polymers

Claim 5 narrows claim 4 to Formula III and specifies numerical ranges for:

n, from 5 to 400;
p and q, each from about 1 to 20;
s, from 0 to 10;
t, from 2 to 30;
x, from 1 to 100; and
y, from 2 to 30.

This claim is more vulnerable to noninfringement through polymer design changes, particularly changes to the repeat-unit architecture, linker identity, or chain-length distribution. It may nevertheless be commercially important if the accused formulation uses a disclosed or closely related polyorthoester platform.

Claim 6: semi-solid compositions

Claim 6 requires a semi-solid composition. The patent therefore reaches beyond conventional low-viscosity injectable solutions if the formulation has a semi-solid consistency before administration or under the relevant conditions.

The term “semi-solid” may create factual disputes based on:

Viscosity;
Temperature;
Shear rate;
Storage conditions;
Syringeability;
Gelation behavior; and
The point at which physical state is measured.

A formulation that is liquid during administration but semi-solid during storage could present a claim-construction issue.

Claim 7: solubilized active agent

Claim 7 covers compositions in which the anesthetic is solubilized. Claim 1 already covers dispersed or solubilized active agent, so claim 7 appears to provide a narrower species within the broader genus.

The practical value of claim 7 is evidentiary. It may provide a more direct infringement theory for a homogeneous formulation in which analytical testing shows that no separate anesthetic particles are present.

What formulations are protected by Patent 10,980,886?

The patent’s claim architecture covers several formulation categories:

Formulation type	Potential coverage
Bupivacaine in polyorthoester, NMP, and subequimolar maleic acid	High
Ropivacaine in the same platform	High
Lidocaine or mepivacaine in the same platform	Within claim 1 if all limitations are met
Fully crystalline anesthetic suspension	Potentially outside claim 1 because of the crystal limitation
Formulation using DMSO instead of NMP	Within claim 1
Formulation using a solvent other than NMP or DMSO	Outside the literal solvent limitation
Formulation using hydrochloric acid instead of maleic acid	Outside the literal acid limitation
Formulation with equimolar or excess maleic acid	Potentially outside the literal ratio limitation
Polyorthoester-free formulation	Outside the claims
Fully neutralized anesthetic maleate	Potentially outside the mixed salt-base limitation

The word “comprising” prevents a competitor from avoiding the claim merely by adding a second solvent or polymer. Avoidance generally requires removal or alteration of a required claim element.

When does Patent 10,980,886 lose exclusivity?

The patent’s enforceable term cannot be determined from the claims alone. The relevant date is generally 20 years from the earliest effective nonprovisional U.S. filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other statutory adjustments.[1]

The grant date, April 20, 2021, does not determine the expiration date. A patent issued in 2021 could expire substantially earlier or later depending on its priority chain and prosecution history. Any commercial exclusivity analysis should therefore distinguish:

Patent expiration;
FDA regulatory exclusivity;
Orange Book listing status;
Pediatric exclusivity;
Patent-term extension;
Patent-term adjustment; and
Litigation or settlement restrictions.

The supplied claims do not establish any of those dates.

What is the FDA and Orange Book relevance?

The claims are directed to a drug formulation, so FDA regulatory status depends on the particular finished product and its approval pathway.

For an approved drug product, relevant regulatory issues include:

Whether the product is approved under an NDA;
Whether the formulation is listed in the Orange Book;
Whether the patent is listed against the approved drug;
Whether the listed patent claims the drug substance, drug product, or method of use;
Whether a generic applicant would submit a Paragraph IV certification; and
Whether a 30-month stay would arise from timely patent litigation.

An ANDA applicant generally must certify against listed patents under section 505(j) of the Federal Food, Drug, and Cosmetic Act. A Paragraph IV certification can trigger patent litigation if the NDA holder or patent owner files suit within the statutory period.[2]

Patent 10,980,886 is not automatically an Orange Book barrier merely because it claims a local-anesthetic formulation. Listing depends on the relationship between the patent claims and an approved product. If the patent is listed against a product such as an extended-release bupivacaine formulation, an ANDA applicant could face a formulation patent challenge even if the active ingredient itself is off patent.

Which companies could challenge the patent?

Potential challengers would include:

Generic injectable-drug manufacturers;
Specialty pharmaceutical companies developing extended-release local anesthetics;
Contract manufacturers seeking to commercialize a comparable dosage form;
NDA sponsors pursuing a 505(b)(2) application; and
Companies developing depot formulations of bupivacaine or ropivacaine.

The likely challenge routes differ:

Route	Primary issue
ANDA	Whether the proposed generic product meets the reference product’s formulation and bioequivalence requirements
505(b)(2) NDA	Ability to rely partly on existing findings while pursuing a modified formulation or delivery profile
IPR	Patentability of the claims based on printed prior art
District-court litigation	Literal infringement, equivalents, validity, and enforceability
Declaratory judgment	Noninfringement or invalidity where jurisdictional requirements are met

The most plausible invalidity arguments would concern anticipation or obviousness based on prior polyorthoester local-anesthetic formulations, acidified anesthetic systems, solvent selection, and routine experimentation directed to preventing crystallization.

How strong is the patent estate?

Patent 10,980,886 has meaningful formulation value but its enforceability depends heavily on the technical proof required for the mixed salt-base and crystal-free limitations.

Strengths

Claim 1 covers eight amino-amide anesthetics.
The claim covers both dispersed and solubilized active agent.
NMP and DMSO provide alternative solvent routes.
The claim is open-ended and can tolerate additional formulation components.
The bupivacaine and ropivacaine species have direct commercial relevance.
The claim does not require a particular dose or administration site.

Vulnerabilities

“Mixed salt-base” may require complex analytical proof.
“Substantially free of crystals” may be difficult to apply consistently.
The subequimolar maleic-acid requirement creates a measurable design-around axis.
The solvent limitation excludes formulations using other solvent systems.
The polyorthoester limitation excludes non-polyorthoester delivery platforms.
The patent may face prior-art combinations involving known polyorthoesters, local anesthetics, maleic acid, and aprotic solvents.
Claim 3 may create ambiguity concerning whether the free-base addition requirement is a product limitation or a manufacturing limitation.

The estate is stronger against a formulation that closely reproduces the claimed chemistry than against a competitor using a different polymer, acid, solvent, or drug-salt strategy.

What generic entry risks exist?

A generic or follow-on developer faces four principal risks.

Formulation infringement

A product containing bupivacaine, a polyorthoester, NMP or DMSO, and subequimolar maleic acid could satisfy claim 1 even if it uses a different concentration, syringe, vial, preservative system, or administration protocol.

Paragraph IV litigation

If the patent is listed against an approved reference product, a Paragraph IV certification could lead to litigation and a potential 30-month stay. The commercial effect would depend on the patent’s actual expiration date and the timing of approval.

Analytical uncertainty

The mixed salt-base and crystal-free limitations may require testing of the accused product. A generic applicant could dispute whether the claimed chemical state exists in the finished dosage form.

Regulatory mismatch

A formulation that avoids the patent may no longer be pharmaceutically equivalent to the reference product. A change from NMP to another solvent, from maleic acid to another acid, or from polyorthoester to another biodegradable polymer could require a 505(b)(2) pathway rather than a conventional ANDA.

How does this patent compare with conventional bupivacaine patents?

Issue	Patent 10,980,886	Conventional bupivacaine patent
Subject matter	Polyorthoester formulation	May claim drug substance, dosage, method, or delivery system
Active ingredient	Multiple amino-amide anesthetics	Often bupivacaine-specific
Polymer requirement	Required	Often absent
Maleic acid	Required	Often absent
NMP or DMSO	Required	Often absent
Crystal limitation	Required	Usually absent
Dose limitation	Not stated in supplied claims	May be central
Route of administration	Not stated in supplied claims	May be central
Design-around options	Change polymer, acid, solvent, or physical state	Often narrower or broader depending on claim type

This patent should be analyzed as one layer of a formulation estate. It does not replace separate review of drug-product patents, delivery-device patents, method-of-use patents, manufacturing patents, and any patents covering specific extended-release commercial products.

What manufacturing and intellectual-property barriers remain?

The polymer chemistry may create barriers independent of the asserted claims. A competitor may need to control:

Polyorthoester monomer sourcing;
Polymer molecular-weight distribution;
Residual monomer levels;
Solvent removal and water control;
Sterile compounding;
Injectable viscosity;
Anesthetic loading;
Crystal suppression;
Stability during storage;
Syringeability; and
In-process analytical control.

These manufacturing issues can extend practical exclusivity even when a competitor identifies a noninfringing formulation. A noninfringing product must still meet FDA requirements for sterility, impurities, extractables and leachables, stability, container closure, and clinical performance.

Key Takeaways

Patent 10,980,886 is a formulation patent centered on polyorthoester, maleic acid, NMP or DMSO, and specified amino-amide anesthetics.
Claim 1 is broad across eight anesthetics but requires a subequimolar maleic-acid ratio, mixed salt-base state, and substantial absence of anesthetic crystals.
Claims 2 through 7 narrow the invention to bupivacaine or ropivacaine, free-base addition, specified polyorthoester structures, semi-solid formulations, and solubilized drug.
The patent does not, based on the supplied claims, require a specific dose, administration route, release duration, device, or second active ingredient.
The principal design-around options are changing the polymer, acid, solvent, drug form, or physical state.
Orange Book impact depends on whether the patent is listed against an approved reference product. Patent issuance alone does not establish an Orange Book barrier.
The patent’s expiration date cannot be derived from the claims or grant date alone.
The highest litigation risk concerns a bupivacaine or ropivacaine depot formulation that reproduces the claimed chemistry.
The most material validity and claim-construction disputes are likely to concern prior art, “mixed salt-base,” “substantially free of crystals,” and the interpretation of claim 3.

FAQs About United States Patent 10,980,886

Does Patent 10,980,886 cover ordinary bupivacaine injection?

No. Ordinary bupivacaine injection does not fall within the supplied claims unless it also contains the claimed polyorthoester, maleic acid, NMP or DMSO, subequimolar acid ratio, mixed salt-base state, and crystal limitation.

Can a formulation avoid the patent by using lidocaine instead of bupivacaine?

Not necessarily. Lidocaine is expressly listed in claim 1. Substitution avoids the patent only if the resulting formulation fails another required limitation or falls outside the claim’s construction.

Does using DMSO instead of NMP avoid infringement?

No. DMSO is expressly identified as an alternative solvent in claim 1.

Does a formulation with maleic acid at a one-to-one molar ratio fall within claim 1?

It may fall outside the literal “less than an equimolar amount” limitation. The outcome would depend on the measured composition and any argument under the doctrine of equivalents.

Are biosimilars relevant to this patent?

No. Bupivacaine, ropivacaine, and the other listed anesthetics are small-molecule drugs, not biologics. The relevant competitive pathways are generics, 505(b)(2) products, and follow-on injectable formulations rather than biosimilars.

References

United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term extension resources. https://www.uspto.gov
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application submissions: Patent certifications and 30-month stays. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda
United States Patent and Trademark Office. (2021). United States Patent No. 10,980,886. https://patents.google.com/patent/US10980886B2/en

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Heron Theraps Inc	ZYNRELEF KIT	bupivacaine; meloxicam	SOLUTION, EXTENDED RELEASE;PERIARTICULAR	211988-001	May 12, 2021		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
Heron Theraps Inc	ZYNRELEF KIT	bupivacaine; meloxicam	SOLUTION, EXTENDED RELEASE;PERIARTICULAR	211988-002	May 12, 2021		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
Heron Theraps Inc	ZYNRELEF KIT	bupivacaine; meloxicam	SOLUTION, EXTENDED RELEASE;PERIARTICULAR	211988-003	May 12, 2021		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
Heron Theraps Inc	ZYNRELEF KIT	bupivacaine; meloxicam	SOLUTION, EXTENDED RELEASE;PERIARTICULAR	211988-004	May 12, 2021		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Cyprus	1123720	⤷ Start Trial
Denmark	3134070	⤷ Start Trial
European Patent Office	3134070	⤷ Start Trial
European Patent Office	3785700	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 10,980,886

Which drugs does patent 10,980,886 protect, and when does it expire?

Summary for Patent: 10,980,886